Eli Lilly CEO responds to "AI will conquer cancer within a decade": The vision is great, but it's unlikely礼来 CEO 回应“AI 十年内攻克癌症”:愿景很美好,但不太可能
According to IT Home on 14 November, Eli Lilly Chairman and CEO Dave Ricks posted a tweet on X on 12 November in response to Anthropic CEO...
IT之家 11 月 14 日消息,礼来(Eli Lilly)董事长兼首席执行官戴夫 · 里克斯(Dave Ricks)于 11 月 12 日在 X 平台发布推文,回应 Anthropic 首席执行官达…

Key Points要点速览
According to a report from IT Home on 14 November, Eli Lilly Chairman and CEO Dave Ricks posted a tweet on X on 12 November in response to Anthropic CEO Dario Amodei's prediction that "AI will conquer diseases such as cancer in less than a decade", stating that this vision is "desirable" but unlikely to be realised. As previously reported by IT Home, in a roadshow video for investors, Amodei stated that cancer, Alzheimer's disease, heart disease, and mental illnesses are expected to become "a thing of the past" in less than a decade. This optimistic assessment of the prospects for AI in healthcare has raised questions among members of the medical community. In his tweet, Ricks stated: "While this vision is indeed appealing, I believe it is unlikely to come to fruition." He stated that there are still significant gaps in human understanding of biology, and obtaining reliable evidence through randomised human trials remains a key bottleneck in determining the progress of research and development. Ricks also said that he is excited about the application of AI in the pharmaceutical industry, but he expects progress to be more likely to be "steady and gradual". In other words, finding candidate drugs more quickly does not mean that their safety and efficacy for patients can be proven just as quickly; there is still a validation process that must be completed before laboratory discoveries can be used for actual treatment. Dave Ricks, Chairman and CEO of Eli Lilly. Image source: Eli Lilly. Founded in 1876 and headquartered in Indianapolis, USA, Eli Lilly sells its products in approximately 90 countries and operates in areas such as cardiovascular and metabolic diseases, oncology, immunology, and neuroscience. Eli Lilly is one of the world's most influential innovative pharmaceutical companies and a key player in the field of diabetes and obesity treatment. Its significance stems not only from its size, but also from its long-standing experience in turning medical discoveries into medicines, completing clinical trials, and bringing them to global markets.
IT之家 11 月 14 日消息,礼来(Eli Lilly)董事长兼首席执行官戴夫 · 里克斯(Dave Ricks)于 11 月 12 日在 X 平台发布推文,回应 Anthropic 首席执行官达里奥 · 阿莫代伊(Dario Amodei)有关“AI 将在不到十年内攻克癌症等疾病”的预测, 称这一愿景“令人向往”,但实现的可能性不大。 IT之家此前报道,在面向投资者的路演视频中,阿莫代伊表示癌症、阿尔茨海默病、心脏病和精神疾病,有望在不到十年内成为“过去式”。 这番对 AI 医疗前景的乐观判断,引发医药界人士质疑 。 里克斯在推文中表示:“如果这个愿景真得令人向往,但是我认为这不太可能发生”。他表示人类对生物学的认识仍有大片空白,而通过随机人体试验获取可靠证据,依然是决定研发进度的关键瓶颈。 里克斯同时表示,自己对 AI 在医药行业的应用感到振奋,但预计进展更可能是“稳步、渐进的”。换言之,更快找到候选药物,并不意味着可以同样迅速地证明它对患者安全、有效;实验室发现距离真正用于治疗,仍有必须完成的验证过程。 礼来(Eli Lilly)董事长兼首席执行官戴夫 · 里克斯(Dave Ricks),图源:礼来 礼来创立于 1876 年,总部位于美国印第安纳波利斯,产品销往约 90 个国家,业务覆盖心血管与代谢疾病、肿瘤、免疫和神经科学等领域。礼来(Eli Lilly)是全球最具影响力的创新药企业之一, 也是糖尿病和肥胖症治疗领域的核心玩家 。它的分量不仅来自规模,更来自把医学发现变成药物、完成临床验证并推向全球市场的长期经验。
想马上用起来?去「AI工具」栏挑一个直接下载,或在「AI教程」里跟着图文步骤做一遍。
去 AI工具 → 看 AI教程 →阅读与点赞数据保存在你的浏览器本地,欢迎留下你的想法。
今日正能量学一点,用一点;今天种下的种子,会长成明天的能力。去免费下载专区 →广告
评论 文明发言,让讨论更有价值